Iovance Biotherapeutics, Inc. filings document a biotechnology company focused on polyclonal TIL therapies, including disclosures tied to Amtagvi, Proleukin, lifileucel, and broader solid-tumor cell therapy programs. Its Form 8-K reports cover operating results, financial condition, corporate presentations, clinical or regulatory disclosures, and material-event updates.
The filing record also includes proxy materials covering director elections, executive compensation, shareholder voting matters, and board governance. Capital-structure disclosures include common stock matters, registration-statement references, and material agreements related to an at-the-market offering program.
IOVANCE BIOTHERAPEUTICS, INC. Chief Commercial Officer Kirby Daniel Gordon reported routine equity compensation activity. On May 11, 2026, 10,000 restricted stock units (RSUs) vested and converted into common stock, with 2,435 shares withheld by the company to cover mandatory tax obligations rather than sold on the market.
After these transactions, Gordon directly holds 146,946 shares of common stock and 70,004 RSUs, which the filing states will vest in equal quarterly installments. The activity reflects compensation vesting and tax withholding, not open-market buying or selling.
State Street Corporation reports beneficial ownership of 17,448,108 shares of Iovance Biotherapeutics common stock, representing 4.2% as of 03/31/2026.
The filing shows shared voting power of 16,532,266 shares and shared dispositive power over 17,448,108 shares. The Schedule 13G lists several State Street advisory subsidiaries as the reporting entities. The signature block is dated 05/12/2026.
Iovance Biotherapeutics reported first quarter 2026 revenue of about $71.4 million, approximately 45% higher than a year earlier, reflecting strong demand for Amtagvi. The company issued revenue guidance of $86–88 million for the second quarter and $350–370 million for full-year 2026, signaling expectations for continued growth.
Iovance remains unprofitable, with a net loss of $79.0 million and a loss per share of $0.19, though both improved versus 2025. Management highlighted internal manufacturing efficiencies, cost reductions, and a 40% confirmed objective response rate in metastatic serous endometrial cancer as it advances multiple TIL therapy trials. Cash, cash equivalents, and investments totaled $313.4 million as of March 31, 2026.
Iovance Biotherapeutics reported Q1 2026 net product revenue of $71.4 million, primarily from its TIL therapy Amtagvi and IL‑2 product Proleukin, up from $49.3 million a year earlier. Amtagvi contributed $60.2 million and Proleukin $11.2 million.
The company posted a net loss of $79.0 million, improved from a $116.2 million loss in Q1 2025, as operating expenses and stock-based compensation declined. Cash, cash equivalents, short‑term investments and restricted cash totaled $319.4 million, and management believes this is sufficient to fund planned operations for at least the next twelve months while it continues commercial expansion and late‑stage trials in melanoma and other solid tumors.
Iovance Biotherapeutics is asking stockholders to approve seven proposals at its 2026 virtual-only annual meeting on June 10, 2026. Holders of 446,502,396 shares of common stock as of April 15, 2026 can vote online, by phone, mail, or during the webcast.
Stockholders will vote on re-electing six directors, an advisory “say on pay” for named executive officers, and how often to hold future say-on-pay votes. They will also consider ratifying Ernst & Young LLP as auditor for 2026, adding 1,000,000 shares to the 2020 Employee Stock Purchase Plan, increasing authorized common stock from 500,000,000 to 650,000,000 shares, and a potential adjournment to solicit more proxies if Proposal 6 lacks support.
Iovance Biotherapeutics, Inc. is soliciting proxies for its 2026 Annual Meeting to be held virtually at 11:00 a.m. Eastern on June 10, 2026. The record date is April 15, 2026, and 446,502,396 shares of common stock were outstanding as of that date. Agenda items include election of seven directors, ratification of Ernst & Young LLP as auditor, advisory "say on pay" votes, an increase to the 2020 Employee Stock Purchase Plan by 1,000,000 shares (Proposal 5), and a proposed amendment to increase authorized common shares from 500,000,000 to 650,000,000 (Proposal 6), with a related adjournment proposal (Proposal 7) to solicit additional proxies if needed.
Iovance Biotherapeutics Schedule 13G/A (Amendment No. 6) reports that The Vanguard Group holds 0 shares of Common Stock, representing 0% ownership. The filing explains an internal realignment effective January 12, 2026, after which certain Vanguard subsidiaries report beneficial ownership separately.
Iovance Biotherapeutics, Inc. reported that board member Wendy Yarno has notified the Board she will retire and will not stand for re-election at the company’s annual meeting of stockholders, which is anticipated to be held in June 2026.
Ms. Yarno will continue to serve as a director until the annual meeting. The company stated that her decision to retire is not due to any disagreement with Iovance regarding its operations, policies, or practices, and publicly thanked her for her service on the Board.
Roche Corleen M. reported acquisition or exercise transactions in this Form 4 filing.
IOVANCE BIOTHERAPEUTICS, INC. reported that its Chief Financial Officer, Corleen M. Roche, received a grant of 132,200 restricted stock units (RSUs) on common stock as equity compensation. Each RSU represents the right to receive one share of common stock if vesting conditions are met.
These RSUs vest over three years, with one-third vesting on the one-year anniversary of the grant date. The remaining RSUs then vest in eight equal quarterly installments over the following two years, provided she remains employed with the company on each vesting date.